{"id":"W2111333004","doi":"10.1016/s1081-1206(10)60386-9","title":"Tolerability of indacaterol, a novel once-daily β2-agonist, in patients with asthma: a randomized, placebo-controlled, 28-day safety study","year":2007,"lang":"en","type":"article","venue":"Annals of Allergy Asthma & Immunology","topic":"Asthma and respiratory diseases","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":false,"ca_institutions":"Ottawa Allergy Research Corporation","funders":"","keywords":"Indacaterol; Tolerability; Medicine; Placebo; Adverse effect; Anesthesia; Agonist; Randomized controlled trial; Formoterol; Internal medicine; Asthma; Inhalation; Bronchodilator","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002389601,0.00155032,0.003863696,0.0004004877,0.0006304603,0.0010458,0.0008732138,0.001990632,0.002693171],"category_scores_gemma":[0.001999347,0.0009803445,0.002519052,0.0003912152,0.001429183,0.001574389,0.0004059198,0.003601256,0.0005615561],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006269338,"about_ca_system_score_gemma":0.0006608681,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004446528,"about_ca_topic_score_gemma":0.0006687651,"domain_scores_codex":[0.9988948,0.0005538161,0.00009295408,0.0001983764,0.0001519762,0.000108125],"domain_scores_gemma":[0.9980391,0.000551511,0.0005990113,0.0002363646,0.0001302545,0.0004437294],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9614919,0.009330182,0.003258565,0.0003951974,0.001111662,0.000060876,0.00007664087,0.0003202,0.008788708,0.00003132021,0.0003137936,0.01482095],"study_design_scores_gemma":[0.7362664,0.2393782,0.01945554,0.00002346597,0.001403902,0.0001291655,0.0000494599,0.0007224861,0.001967891,0.0000725559,0.0004875633,0.00004337344],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9960537,0.00199604,0.0003479159,0.0001533418,0.00009707536,0.0004777064,0.0004145674,0.00004463089,0.0004148814],"genre_scores_gemma":[0.996491,0.0009043078,0.0004395808,0.0003765716,0.0003164163,0.0004614296,0.000451475,0.00001696404,0.0005422114],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003863696,"threshold_uncertainty_score":0.01263756,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01306753768989584,"score_gpt":0.273793775620833,"score_spread":0.2607262379309372,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}